Search Results - "Haberkorn, B. C. M"

Real Life Data and Outcome of FOLFIRINOX Use in Metastatic Pancreatic Cancer Patients in General Hospitals in the Netherlands by Haberkorn, B.C.M., Hoogendijk, L., Loosveld, O.S., Thijs, A. M. J., Verstijnen, J.

“…Introduction Pancreatic cancer is one of the five most common causes of cancer mortality in developed countries. In patients with metastatic disease, the most…”
Get full text

Real-world outcomes of first-line chemotherapy for unresectable stage III and IV bladder cancer by Reesink, Daan J., van Melick, Harm H. E., van der Nat, Paul B., Los, Maartje, Horenblas, Simon, van de Garde, Ewoudt M. W.

“…Purpose For many malignancies, considerable divergence between the efficacy found in clinical trials and effectiveness in routine practice have been reported…”
Get full text

Hospital variation in treatment patterns and oncological outcomes for patients with muscle-invasive and metastatic bladder cancer in the Netherlands by Reesink, Daan J., van de Garde, Ewoudt M. W., van der Nat, Paul, Somford, Diederik M., Los, Maartje, Horenblas, Simon, van Melick, Harm H. E.

“…Purpose Population-based studies on treatment patterns in oncology and corresponding clinical outcomes can help identify strategies towards optimal value for…”
Get full text

Uitkomsten in de dagelijkse praktijk van eerstelijnschemotherapie voor niet-resectabel stadium III en IV urotheelcarcinoom van de blaas by Reesink, Daan J., van de Garde, Ewoudt M. W., van der Nat, Paul B., Los, Maartje, Horenblas, Simon, van Melick, Harm H. E.

“…Samenvatting Dit onderzoek evalueert de kloof tussen de werkzaamheid ( efficacy ) van palliatieve eerstelijns (1L) chemotherapiebehandeling (CTx) voor…”
Get full text

Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial by van Dam, J L, Verkolf, E M M, Dekker, E N, Bonsing, B A, Bratlie, S O, Brosens, L A A, Busch, O R, van Driel, L M J W, van Eijck, C H J, Feshtali, S, Ghorbani, P, de Groot, D J A, de Groot, J W B, Haberkorn, B C M, de Hingh, I H, van der Holt, B, Karsten, T M, van der Kolk, M B, Labori, K J, Liem, M S L, Loosveld, O J L, Molenaar, I Q, Polée, M B, van Santvoort, H C, de Vos-Geelen, J, Wumkes, M L, van Tienhoven, G, Homs, M Y V, Besselink, M G, Wilmink, J W, Groot Koerkamp, B

“…Surgical resection followed by adjuvant mFOLFIRINOX (5-fluorouracil with leucovorin, irinotecan, and oxaliplatin) is currently the standard of care for…”
Get full text

Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer by Dekker, E. N, Busch, O. R, Labori, K. J, Haberkorn, B. C. M, van der Holt, B, Wilmink, J. W, Feshtali, S, Besselink, M. G, van Eijck, C. H. J, van Tienhoven, G, van der Kolk, M. B, van Dam, J. L, Bratlie, S. O, Liem, M. S. L, de Hingh, I. H, Homs, M. Y. V, de Vos - Geelen, J, de Groot, J. W. B, Polée, M. B, de Groot, D. J. A, van Santvoort, H. C, Bonsing, B. A, Verkolf, E. M. M, Karsten, T. M, Groot Koerkamp, B, Ghorbani, P, van Driel, L. M. J. W, Molenaar, I. Q, Brosens, L. A. A, Loosveld, O. J. L, Wumkes, M. L

“…Background Surgical resection followed by adjuvant mFOLFIRINOX (5-fluorouracil with leucovorin, irinotecan, and oxaliplatin) is currently the standard of care…”
Get full text

855PEffect of prednisone on docetaxel pharmacokinetics in metastatic prostate cancer: A randomized drug-drug interaction study by Belderbos, B P S I, Hussaarts, K G A M, van Harten, L, Oomen-De Hoop, E, de Bruijn, P, Hamberg, P, van Alphen, R J, Haberkorn, B C M, van Soest, R J, de Wit, R, Mathijssen, R H J

Get full text

Impact of nationwide enhanced implementation of best practices in pancreatic cancer care (PACAP-1): a multicenter stepped-wedge cluster randomized controlled trial by Mackay, T M, Smits, F J, Latenstein, A E J, Bogte, A, Bonsing, B A, Bos, H, Bosscha, K, Brosens, L A A, Hol, L, Busch, O R C, Creemers, G J, Curvers, W L, den Dulk, M, van Dieren, S, van Driel, L M J W, Festen, S, van Geenen, E J M, van der Geest, L G, de Groot, D J A, de Groot, J W B, Haj Mohammad, N, Haberkorn, B C M, Haver, J T, van der Harst, E, Hemmink, G J M, de Hingh, I H, Hoge, C, Homs, M Y V, van Huijgevoort, N C, Jacobs, M A J M, Kerver, E D, Liem, M S L, Los, M, Lubbinge, H, Luelmo, S A C, de Meijer, V E, Mekenkamp, L, Molenaar, I Q, van Oijen, M G H, Patijn, G A, Quispel, R, van Rijssen, L B, Römkens, T E H, van Santvoort, H C, Schreinemakers, J M J, Schut, H, Seerden, T, Stommel, M W J, Ten Tije, A J, Venneman, N G, Verdonk, R C, Verheij, J, van Vilsteren, F G I, de Vos-Geelen, J, Vulink, A, Wientjes, C, Wit, F, Wessels, F J, Zonderhuis, B, van Werkhoven, C H, van Hooft, J E, van Eijck, C H J, Wilmink, J W, van Laarhoven, H W M, Besselink, M G

“…Pancreatic cancer has a very poor prognosis. Best practices for the use of chemotherapy, enzyme replacement therapy, and biliary drainage have been identified…”
Get full text

Effect of prednisone on docetaxel pharmacokinetics in metastatic prostate cancer: A randomized drug-drug interaction study by Belderbos, B.P.S.I., Hussaarts, K.G.A.M., van Harten, L., Oomen-De Hoop, E., de Bruijn, P., Hamberg, P., van Alphen, R.J., Haberkorn, B.C.M., van Soest, R.J., de Wit, R., Mathijssen, R.H.J.

Get full text